Neena Varghese
Primary Care · Sacaton, AZNPI 1730792482
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,259 of the $6,007 with a category attached, or 87.5%. It is spread thinly across 32 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,376 and has fallen 84.6% since, to $366 in 2025. Among primary care clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 246 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impulse Dynamics (USA) Inc.$751
- Biotronik Inc.$646
- Novartis$548
- Johnson & Johnson$343
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$337
- Heartflow, Inc.$302
- plus $3K from 26 others
What the payments were for
- Consulting fees$5008%
- Food & beverage$5,25988%
- Education$2484%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Impulse Dynamics (USA) Inc. | 9 | $751 |
| Biotronik Inc. | 47 | $646 |
| Novartis | 33 | $548 |
| Johnson & Johnson | 22 | $343 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $337 |
| Heartflow, Inc. | 3 | $302 |
| Merck | 18 | $278 |
| Corcept Therapeutics | 6 | $263 |
| Lilly USA, LLC | 4 | $249 |
| Sanofi-aventis U.S. LLC | 12 | $241 |
| AstraZeneca | 11 | $231 |
| Novo Nordisk | 13 | $222 |
| Boston Scientific | 6 | $217 |
| Boehringer Ingelheim | 8 | $166 |
| E.r. Squibb & Sons, L.L.C. | 2 | $155 |
| Cvrx, Inc. | 8 | $140 |
| Altathera Pharmaceuticals LLC | 1 | $139 |
| Pfizer | 7 | $135 |
| Madrigal Pharmaceuticals | 1 | $128 |
| Actelion Pharmaceuticals US, Inc. | 1 | $105 |
| Medtronic | 3 | $76 |
| Irhythm Technologies, Inc. | 4 | $65 |
| Insulet Corporation | 2 | $46 |
| Dexcom, Inc. | 2 | $43 |
| Amgen | 2 | $37 |
| Kestra Medical Technology Services, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Tandem Diabetes Care, Inc. | 2 | $23 |
| Mannkind Corporation | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Cequr Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER SMART SYSTEM$628
- FFRct$290
- Sotalol Hydrochloride$139
- CAMZYOS$131
- REZDIFFRA$128
- LifeVest$126
- Varithena Administration Pack$125
- MOUNJARO$122
- UPTRAVI$105
- OPSUMIT$105
How this compares
$6,007 in reported general payments places this provider in the 95th percentile of 151 primary care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 100 | $104,182 |
| JardianceEmpagliflozin | 33 | $36,192 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $3,765 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $3,121 |
| LantusInsulin Glargine,hum.Rec.Anlog | 16 | $2,549 |
| Metformin Hcl ErMetformin Hcl | 46 | $783 |
| Atorvastatin Calcium | 17 | $644 |
| Glimepiride | 16 | $94 |
| Amlodipine Besylate | 15 | $62 |
| Pioglitazone Hcl | 14 | $56 |
| Lisinopril | 13 | $43 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $222 | $104,182100 claims |
| Boehringer IngelheimJardiance | $166 | $36,19233 claims |
| Sanofi-aventis U.S. LLCLantus | $241 | $2,54916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 151 primary care providers in Arizona.
Other primary care in Sacaton
- Trey PowrzanasPhoenix$16K
- Christine Rocks-LopezPhoenix$14K
- Elena KlimovaPhoenix$8K
- Albert VillafaniaPhoenix$8K
- Daniela HaimovPhoenix$8K
- Lea NickolasAvondale$7K
- Katy DodtQueen Creek$5K
- Mercy GeorgeQueen Creek$5K
- Charity CorreaPhoenix$5K
- Whitney RosaPrescott Valley$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.